Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ: NASDAQ:SUPN), a company specializing in central nervous system (CNS) therapies, has announced the U.S. Food and Drug Administration (FDA) acceptance of its resubmitted new drug application (NDA) for SPN-830, an apomorphine infusion device aimed at treating Parkinson’s disease motor fluctuations. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 1, 2025, to complete its review.
The device is designed for the continuous treatment of "OFF episodes" in Parkinson's disease, which are periods when medication effectiveness wanes, leading to increased symptoms. The acceptance of the resubmission by the FDA indicates the start of the regulatory review process.
Supernus Pharmaceuticals' portfolio includes approved treatments for various CNS conditions, such as epilepsy, migraine, ADHD, and movement disorders associated with Parkinson’s disease. The company is also actively developing new CNS product candidates for conditions including epilepsy, depression, and other disorders.
The FDA’s PDUFA date is a deadline by which the FDA aims to complete its review of the NDA. It is part of the agency's commitment to expedite the drug approval process while maintaining strict safety and efficacy standards.
The press release from Supernus Pharmaceuticals includes forward-looking statements that are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These include the company's ability to increase profitability, raise capital, commercialize products, and obtain regulatory approvals for new drugs, including SPN-830.
The company's focus on innovation and treatment of CNS diseases continues to be a driving force in its operations and research activities. As with all pharmaceutical companies, Supernus' success in bringing new treatments to market is subject to rigorous regulatory review and market acceptance.
This news article is based on a press release statement from Supernus Pharmaceuticals, Inc.
In other recent news, Supernus Pharmaceuticals reported robust growth in Q2 2024, with significant increases in net sales and positive cash flow. The company's key growth drivers, Qelbree and GOCOVRI, contributed to a substantial rise in prescriptions and net sales. Despite generic competition for Trokendi XR, Supernus raised its full-year 2024 financial guidance and highlighted a strong pipeline with several upcoming catalysts.
Qelbree prescriptions saw a 26% increase with net sales up by 92%, while GOCOVRI net sales rose to $32 million, marking a 10% increase from the previous year. The total revenue for Q2 2024 reached $168.3 million, a 24% increase year-over-year, and adjusted operating earnings for the quarter were $67.7 million, up 67% from the same period last year.
The company also raised its full-year 2024 financial guidance, with total revenue expected between $600 million to $625 million. Supernus has a strong balance sheet with no debt and $347.2 million in cash, cash equivalents, and marketable securities. The company is confident in the resubmission of SPN-830 and expects approval, with positive updates on SPN-817 and SPN-820 anticipated.
InvestingPro Insights
As Supernus Pharmaceuticals (NASDAQ: SUPN) progresses with its resubmitted NDA for SPN-830, the company's financial health and market performance provide key insights into its potential for future growth. With a market capitalization of $1.9 billion, Supernus is positioned as a significant player in the CNS therapy market. The company's gross profit margin stands impressively high at 88.34% for the last twelve months as of Q2 2024, indicating strong operational efficiency in generating revenue relative to its cost of goods sold.
InvestingPro Tips reveal that Supernus holds more cash than debt on its balance sheet, suggesting a solid financial footing that could support its ongoing research and development efforts. Additionally, analysts have revised their earnings upwards for the upcoming period, reflecting optimism about the company's profitability prospects.
With a P/E ratio of 363.75, the stock is trading at a high earnings multiple, which may indicate investor confidence in the company's growth potential or a premium for its market position in CNS therapies. Notably, the stock has demonstrated robust performance with a strong return over the last three months, up 18.73%, and is trading near its 52-week high, at 97.49% of the peak price.
For readers interested in deeper analysis, there are 14 additional InvestingPro Tips available for Supernus Pharmaceuticals, which can be found at InvestingPro. These tips offer valuable perspectives for both current and prospective investors seeking to understand the company's financial nuances and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.